Table 3.

Group Comparison of change in Participant Ratings of Irritability from Baseline to Days 28 and 60 for Intention-To-Treat Analyses of Amantadine (n=82) Versus Placebo Groups (n=86)

Variable	Group	Mean	Median	SD	p value	Adjusted p value threshold	% improved by >2 points	% difference (95% CI)	p value	Adjusted p value threshold
Baseline to day 28
NPI-I Most Problematic	Placebo	−1.87	−2.00	3.90	0.3488	0.05	40.5%	+10.8% (−4.2% to +25.8%)	0.1662	0.017
	Amantadine	−2.56	−3.00	3.58			51.3%
NPI-I Distress	Placebo	−1.17	−1.00	1.54	0.2807	0.025
	Amantadine	−1.52	−1.00	1.71
NPI-I Most Aberrant post hoc	Placebo	−1.87	−2.00	3.71	0.0539	0.025	70.4%	−10.4% (−24.7% to +3.9%)		0.05
	Amantadine	−2.98	−3.00	3.64			60.0%		0.1672
Baseline to day 60
NPI-I Most Problematic	Placebo	−2.29	−2.00	3.90	0.0353	0.017	48.8%	+11.7% (−3.3% to +26.7%)	0.1373	0.05
	Amantadine	−3.47	−3.00	2.83			60.5%
NPI-I Distress	Placebo	−1.35	−1.00	1.53	0.0362	0.025
	Amantadine	−1.87	−1.00	1.48
NPI-I Most Aberrant post hoc	Placebo	−2.77	−3.00	3.26	0.1216	0.025	53.6%	+6.9% (−8.0% to +21.8%)	0.3750	0.05
	Amantadine	−3.70	−3.50	3.19			60.5%

SD, standard deviation; CI, confidence interval; NPI, Neuropsychiatric Inventory.